A new trading day began on Friday, with Corvus Pharmaceuticals Inc (NASDAQ: CRVS) stock price up 8.95% from the previous day of trading, before settling in for the closing price of $5.81. CRVS’s price has ranged from $1.05 to $6.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 26.34%. With a float of $50.12 million, this company’s outstanding shares have now reached $62.55 million.
Let’s look at the performance matrix of the company that is accounted for 28 employees. In terms of profitability, gross margin is 58.54%, operating margin of -9511.79%, and the pretax margin is -9193.5%.
Corvus Pharmaceuticals Inc (CRVS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Corvus Pharmaceuticals Inc is 19.87%, while institutional ownership is 27.92%. The most recent insider transaction that took place on May 06 ’24, was worth 34,624. In this transaction an insider of this company bought 20,000 shares at a rate of $1.73, taking the stock ownership to the 153,773 shares. Before that another transaction happened on May 06 ’24, when Company’s President and CEO bought 577,634 for $1.73, making the entire transaction worth $1,000,000. This insider now owns 577,634 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 26.34% per share during the next fiscal year.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Here are Corvus Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) saw its 5-day average volume 0.52 million, a positive change from its year-to-date volume of 0.28 million. As of the previous 9 days, the stock’s Stochastic %D was 88.45%. Additionally, its Average True Range was 0.44.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 97.46%, which indicates a significant increase from 92.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.24% in the past 14 days, which was lower than the 83.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.61, while its 200-day Moving Average is $2.65. Nevertheless, the first resistance level for the watch stands at $6.63 in the near term. At $6.93, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.41. If the price goes on to break the first support level at $5.85, it is likely to go to the next support level at $5.37. The third support level lies at $5.07 if the price breaches the second support level.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
With a market capitalization of 395.94 million, the company has a total of 62,551K Shares Outstanding. Currently, annual sales are 0 K while annual income is -27,030 K. The company’s previous quarter sales were 0 K while its latest quarter income was -4,260 K.
